Masimo’s (MASI) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Masimo (NASDAQ:MASI) in a research note published on Wednesday,Benzinga reports.

Several other brokerages have also commented on MASI. Raymond James raised their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Piper Sandler raised their target price on shares of Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Wells Fargo & Company raised their target price on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $194.80.

Masimo Stock Performance

Shares of MASI opened at $188.77 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. Masimo has a one year low of $101.61 and a one year high of $192.62. The company has a 50-day simple moving average of $173.28 and a two-hundred day simple moving average of $153.33. The firm has a market capitalization of $10.11 billion, a PE ratio of 130.19 and a beta of 1.02.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. On average, analysts anticipate that Masimo will post 4.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Masimo

Institutional investors and hedge funds have recently made changes to their positions in the company. Jones Financial Companies Lllp bought a new stake in shares of Masimo during the fourth quarter valued at approximately $27,000. UMB Bank n.a. increased its position in shares of Masimo by 180.9% during the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 123 shares in the last quarter. Trust Co. of Vermont bought a new stake in shares of Masimo during the fourth quarter valued at approximately $33,000. Blue Trust Inc. increased its position in shares of Masimo by 56.3% during the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 71 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 64 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.